Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Aim(s): To assess the systemic treatment of Ki-67 5-10% metastatic GEP-NET.
Materials and methods: Two-hundred and seventeen pts with metastatic GEPNET were attended in a Spanish Medical Oncology Department from 2005-2012. Twenty of these 217 (9%) which had Ki-67 5-10% GEPNET were analysed.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
, Carmona A
, Faez L
, Solis P
, Rodriguez D
, Ruiz L
, Sánchez L
, Li W
, Uriol E
, Menendez M
, Vieitez J
, Garrido M
To read results and conclusion, please login ...
Further abstracts you may be interested in